Business Wire

EXSCIENTIA

Share
Michael Krams, M.D., Joins Exscientia as Chief Quantitative Medicine Officer

Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical development strategy for Exscientia’s portfolio of investigational medicines. Exscientia’s drug discovery platform utilises patient-based translational models and AI-driven molecule design to optimise drug candidates for specific patient populations. As part of these efforts, Dr. Krams will drive work to improve trial design and patient selection within clinical trials to maximise clinical success and patient benefit.

“We want to be as innovative in the clinic as we have been in drug discovery. Mike is a proven innovator and strategic leader at the vanguard of bringing a quantitative science approach to clinical development. He has been a thought leader in the field for more than 20 years, implementing model-informed drug development, increasing the use of biomarkers to enable adaptive trials, and finding better ways to enrich trials for patient selection,” said Andrew Hopkins, DPhil., Exscientia’s founder and CEO. “Focusing our clinical trials on the people that are most likely to benefit from them has the potential to not only improve clinical success rates, but it also advances our mission of putting patients at the centre of creating new medicines.”

Dr. Krams joins Exscientia’s executive leadership team, reporting to Andrew Hopkins, and will be based at Exscientia’s precision medicine centre in Vienna, Austria. Dr. Krams most recently led the Quantitative Sciences group at Janssen R&D, bringing together approximately 500 statisticians, pharmacologists and modellers to enable efficient decision-making in various aspects of drug development. Earlier in his career, he was Vice President of Adaptive Trials and Applied Program Strategies at Wyeth. Dr. Krams holds an M.D. from the University of Munich.

“I’m pleased to join Exscientia, a mission-driven company harnessing artificial intelligence to transform drug discovery and development to make better medicines for patients. In many ways, the work I’ve driven throughout my career is a good match to Exscientia’s goal - asking how conventional, sequential approaches to clinical development can be further improved, aiming for truly patient-driven medicine development. Discovery and clinical strategies need to be closely connected through biomarker strategies and Exscientia’s precision medicine platform has the potential to achieve just that,” said Mike Krams, M.D., Chief Quantitative Medicine Officer for Exscientia.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 30 projects underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI .

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Exscientia’s expectations regarding its management team. Words such as “anticipates,” "believes," “expects,” "intends," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions and no assurance can be given that the drug discovery and precision medicine platforms discussed above will be successful in optimising drug candidates for specific patient populations. The success of Exscientia’s platforms is subject to numerous factors, many of which are beyond the control of Exscientia, including, without limitation, the ability of Exscientia to design clinical trials that are cleared by the FDA and of healthcare providers to collect viable patient tissue samples. Exscientia undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celero Ventures Opens $25 Million Early-Stage Fund to Investors Backing the Next Generation of European Software Companies1.7.2025 09:30:00 CEST | Press release

Celero Ventures, a new venture capital firm founded by experienced software operators Dave Wyatt and Nick Cochran, is now raising its debut $25 million fund to invest in early-stage startups across the UK and Europe. The fund, which is already 25% subscribed, targets pre-seed and seed-stage companies building next-generation AI and data infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701820933/en/ Nick Cochran and David Wyatt (right) Founders of Celero Ventures Based in London, Celero Ventures is inviting limited partners (LPs) to join its mission of backing exceptional technical founders and accelerating their path to product-market fit and scalable growth. Wyatt and Cochran bring a rare combination of deep go-to-market (GTM) experience and startup leadership. Together, they helped scale both MuleSoft and Databricks—two of the most successful enterprise software companies of the past decade. Their experien

3GPP MCX Standards-Based Hytera HyTalk MC 6.0 Released Globally1.7.2025 09:00:00 CEST | Press release

Hytera, a leading global provider of professional communications technologies and solutions, announced the worldwide release of Hytera HyTalk MC 6.0, its new-generation broadband mission-critical communication platform fully compliant with the 3GPP MCX standard Release 18. As a key part of Hytera’s convergence-native communications strategy, it delivers inclusive, efficient and secure communication over LTE cellular network. Hytera HyTalk MC 6.0 leverages 3GPP standard interfaces and Hytera’s proprietary protocols to enable deep interworking across different technologies and vendors. It enables real-time mapping between the signaling of 3GPP MCX and Hytera DMR, and interconnects with HyteraTETRA systems, allowing a smooth migration path to data-rich communications for mission- and business-critical institutions and users. Hytera DMR or TETRA two-way radios can communicate with LTE/5G terminals through the Hytera HyTalk MC platform in a hybrid network. The Ad-Hoc Temporary Group Call fe

Lyten Acquires Europe’s Largest Battery Energy Storage Systems Manufacturing Operation from Northvolt1.7.2025 09:00:00 CEST | Press release

Lyten will take full ownership of Northvolt Dwa ESS, Europe’s largest energy storage systems manufacturing operation, located in Gdansk, Poland. Lyten intends to immediately restart production in Gdansk to resume sales of battery energy storage systems (BESS) and is expanding its product line to include the world’s first BESS powered by lithium-sulfur batteries. This complements Lyten’s previously announced acquisition of Northvolt’s lithium-metal cell manufacturing facility in Silicon Valley to scale its lithium-sulfur battery production. Lyten, the supermaterial applications company and global leader in lithium-sulfur batteries, announced today the acquisition of Northvolt’s Dwa ESS operations in Gdansk, Poland, a 25,000 square meter (270,000 sq ft) battery energy storage systems (BESS) manufacturing and R&D facility. Northvolt Dwa ESS is the largest BESS manufacturing facility in Europe and was part of Northvolt Systems. The financial terms of the acquisition are not being released

Cargill Sets a New Global Benchmark for More Sustainable Cocoa Supply Chains1.7.2025 09:00:00 CEST | Press release

Cargill reimagines the cocoa journey to cut emissions and reduce waste. Cargill today announced a transformation of its global cocoa supply chain, unveiling a series of interconnected investments that reduce carbon emissions, eliminate waste, and boost efficiency from cocoa origin countries in West Africa to processing hubs in Europe. The company’s upgrades span renewable energy, circular logistics, and smart infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701468198/en/ Cargill today announced a transformation of its global cocoa supply chain, unveiling a series of interconnected investments that reduce carbon emissions, eliminate waste, and boost efficiency from cocoa origin countries in West Africa to processing hubs in Europe. “Sustainability isn’t a single project at Cargill—it’s how we operate,” said Emiel van Dijk, Managing Director of Cocoa & Chocolate Europe and West Africa. “From circular waste reu

Pioneering Impact Strategy, Record EM Sustainable Finance (EMSF), Celebrates Its Fourth Anniversary With Strong Outperformance Since Inception1.7.2025 08:00:00 CEST | Press release

Record Currency Management, in partnership with UBS Wealth Management, is proud to celebrate the fourth anniversary of its pioneering Emerging Market Sustainable Finance (EMSF) Strategy. Operating at the intersection of impact investing, Emerging and Frontier Market currencies and private placements, the strategy offers investors an opportunity to achieve financial returns, alongside measurable impact. Since inception, EMSF has grown to over U$1 billion in AUM and delivered positive returns of +18.7% since inception. The strategy has significantly outperformed both USD and local currency EM Debt benchmarks with around 30% lower volatility - reaffirming that investors need not compromise between financial returns and measurable impact. By taking currency risk across a wide universe of emerging and frontier currencies, EMSF helps MDBs and DFIs raise local currency funding. This allows borrowers in Emerging Markets to receive funding in local currency, eliminating FX risk. Simultaneously,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye